Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | TAC-001 |
Synonyms | |
Therapy Description |
TAC-001 comprises T-CpG, a TLR9 agonist, linked to an anti-CD22 antibody, which potentially results in enhanced antitumor immune response (Cancer Res 2021;81(13_Suppl):Abstract nr 1721). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
TAC-001 | TRAAC TAC-001|TAC 001|TAC001 | TLR9 Agonist 9 | TAC-001 comprises T-CpG, a TLR9 agonist, linked to an anti-CD22 antibody, which potentially results in enhanced antitumor immune response (Cancer Res 2021;81(13_Suppl):Abstract nr 1721). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05399654 | Phase Ib/II | TAC-001 | A Dose Escalation and Expansion Study of TAC-001 in Patients With Select Advanced or Metastatic Solid Tumors (INCLINE-101) | Recruiting | USA | AUS | 0 |